Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EOLS 
Evolus Inc (EOLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EOLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $23.57
1 Year Target Price $23.57
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.98% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 589.31M USD | Price to earnings Ratio - | 1Y Target Price 23.57 |
Price to earnings Ratio - | 1Y Target Price 23.57 | ||
Volume (30-day avg) 7 | Beta 0.99 | 52 Weeks Range 8.67 - 17.82 | Updated Date 06/29/2025 |
52 Weeks Range 8.67 - 17.82 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.4% | Operating Margin (TTM) -19% |
Management Effectiveness
Return on Assets (TTM) -9.36% | Return on Equity (TTM) -949.46% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value 651936261 | Price to Sales(TTM) 2.14 |
Enterprise Value 651936261 | Price to Sales(TTM) 2.14 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA -21.5 | Shares Outstanding 64475600 | Shares Floating 54307789 |
Shares Outstanding 64475600 | Shares Floating 54307789 | ||
Percent Insiders 5.46 | Percent Institutions 85.33 |
Analyst Ratings
Rating 3 | Target Price 23.57 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Evolus Inc
Company Overview
History and Background
Evolus, Inc. was founded in 2012. It is a performance beauty company focused on providing physicians and their patients with innovative aesthetic products. The company launched Jeuveauu00ae (prabotulinumtoxinA-xvfs) in the U.S. in 2019 as an alternative to Botoxu00ae.
Core Business Areas
- Aesthetic Products: Development and commercialization of aesthetic products, with a primary focus on neurotoxins.
Leadership and Structure
David Moatazedi serves as President and CEO. The company has a board of directors overseeing the executive team and overall strategy.
Top Products and Market Share
Key Offerings
- Jeuveauu00ae (prabotulinumtoxinA-xvfs): A 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. Competitors include AbbVie (Botox), Galderma (Dysport), and Merz (Xeomin). Evolus has achieved meaningful market share since launch.
Market Dynamics
Industry Overview
The aesthetics market is a large and growing industry, driven by an aging population and increasing demand for non-invasive cosmetic procedures.
Positioning
Evolus positions Jeuveauu00ae as a modern, affordable alternative to Botox, targeting a younger demographic and focusing on price competitiveness.
Total Addressable Market (TAM)
The total addressable market for neurotoxins is estimated to be several billion dollars annually. Evolus is positioned to capture a share of this market by offering a competitively priced alternative.
Upturn SWOT Analysis
Strengths
- Competitive pricing
- Modern brand image targeting younger consumers
- Experienced management team
- Focus on a single product
Weaknesses
- Reliance on a single product
- Relatively new player in the market
- Heavily reliant on physician adoption
- Legal battles over intellectual property
Opportunities
- Expanding into new geographic markets
- Developing new aesthetic products
- Increasing brand awareness through marketing
- Partnerships with medical spas and clinics
Threats
- Competition from established players like AbbVie (Botox)
- Potential for generic botulinum toxin products
- Changes in consumer preferences
- Economic downturn impacting discretionary spending
Competitors and Market Share
Key Competitors
- ABBV
- GALDERMA
- MRZ
Competitive Landscape
Evolus faces significant competition from established players with greater resources. Its competitive advantage lies in its pricing strategy and modern brand image. However, intellectual property disputes and brand recognition remain challenges.
Growth Trajectory and Initiatives
Historical Growth: Evolus has experienced rapid revenue growth since the launch of Jeuveauu00ae.
Future Projections: Future growth is dependent on continued market penetration, new product development, and geographic expansion. Analyst estimates will determine revenue growth and expenses.
Recent Initiatives: Focus on digital marketing, expanding sales force, and forging strategic partnerships.
Summary
Evolus has rapidly grown by offering a lower-priced alternative to Botox. However, it faces strong competition and must navigate intellectual property issues. The company is expanding marketing and sales to increase market share. Its success depends on continued market penetration and brand recognition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Evolus Investor Relations
- Company Filings (SEC)
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evolus Inc
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2018-02-08 | President, CEO & Director Mr. David Moatazedi | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 372 | Website https://www.evolus.com |
Full time employees 372 | Website https://www.evolus.com | ||
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.